Boston Scientific
(NYSE: BSX)
announced on social media that it completed its previously announced acquisition of Bolt Medical.
News of the acquisition’s closing comes just days after the FDA granted 510(k) clearance for the Bolt IVL system on March 25, about two months post-submission (Jan. 27).
The company wrote on LinkedIn: “We have successfully closed the acquisition of Bolt Medical. We look forward to advancing the intravascular lithotripsy (IVL) therapy developed by Bolt which will complement our cardiovascular portfolio by expanding treatment options for coronary and peripheral disease.”
Boston Scientific agreed to acquire Bolt Medical and its IVL technology at the start of this year. Boston Scientific initially developed the concept for the Bolt IVL system, helping establish Bolt Medical in 2019. As a strategic investor, the Marlborough, Massachusetts–based company already had an equity stake of approximately 26%.
On a 100% basis — before considering the existing equity stake and other adjustments — the deal is valued at $600 million upfront with up to an additional $300 million upon achievement of certain regulatory milestones.
With the formal closing of the deal, Boston Scientific enters the IVL space led by Shockwave Medical, part of Johnson & Johnson following a $13.3 billion acquisition in 2024. Other companies, such as FastWave Medical, Vantis Vascular and AVS are making waves in IVL, too.
Abbott received FDA IDE approval for its coronary IVL system last week, adding another big name in medtech to the fray.
Bolt Medical designed its IVL advanced laser-based platform for the treatment of coronary and peripheral artery disease. Its novel application of lithotripsy fractures calcium by creating acoustic pressure waves inside a balloon catheter. The system also includes visible, directional emitters for consistent energy delivery in the treatment of calcified lesions.
